BACKGROUND: During antiretroviral therapy, HIV RNA can be detected in cerebrospinal fluid (CSF) when it is undetectable in plasma, a condition termed 'CSF viral escape'. The aim of the current study was to determine the prevalence and risk factors for CSF viral escape in two large cohorts in the USA. METHODS: A total of 1264 HIV-infected volunteers enrolled in two US cohorts at their most recent visit between 2003 and 2011 were included in this cross-sectional analysis if their HIV RNA level in plasma was less than 50 copies/ml while receiving stable antiretroviral therapy (ART) (>6 months) and if they had HIV RNA measured in CSF at their most recent visit between 2003 and 2011. Potential risk factors were identified using univariable and multivariable regression. RESULTS: CSF viral escape was detected in 55 adults (4.4%; 95% CI: 3.4-5.6), who had a median CSF HIV RNA of 155 copies/ml [interquartile range (IQR: 80-283)]. Patients with or without CSF viral escape had similar rates of neurocognitive impairment (38.2 vs. 37.7%; P = 0.91). CSF viral escape was independently associated with the use of ritonavir-boosted protease inhibitors [odds ratio (OR): 2.0; 95% CI: 1.1-3.8] or unboosted atazanavir (OR: 5.1; 95% CI: 1.3-16.1), CSF pleocytosis (OR: 7.6; 95% CI: 4.2-13.7) and abnormal CSF total protein (OR: 2.1; 95% CI: 1.1-3.7). CONCLUSIONS: In this large study of aviremic patients receiving ART, CSF viral escape was uncommon and was linked to evidence of central nervous system inflammation and the use of protease inhibitors, but not with worse neurocognitive performance.
BACKGROUND: During antiretroviral therapy, HIV RNA can be detected in cerebrospinal fluid (CSF) when it is undetectable in plasma, a condition termed 'CSF viral escape'. The aim of the current study was to determine the prevalence and risk factors for CSF viral escape in two large cohorts in the USA. METHODS: A total of 1264 HIV-infected volunteers enrolled in two US cohorts at their most recent visit between 2003 and 2011 were included in this cross-sectional analysis if their HIV RNA level in plasma was less than 50 copies/ml while receiving stable antiretroviral therapy (ART) (>6 months) and if they had HIV RNA measured in CSF at their most recent visit between 2003 and 2011. Potential risk factors were identified using univariable and multivariable regression. RESULTS: CSF viral escape was detected in 55 adults (4.4%; 95% CI: 3.4-5.6), who had a median CSF HIV RNA of 155 copies/ml [interquartile range (IQR: 80-283)]. Patients with or without CSF viral escape had similar rates of neurocognitive impairment (38.2 vs. 37.7%; P = 0.91). CSF viral escape was independently associated with the use of ritonavir-boosted protease inhibitors [odds ratio (OR): 2.0; 95% CI: 1.1-3.8] or unboosted atazanavir (OR: 5.1; 95% CI: 1.3-16.1), CSF pleocytosis (OR: 7.6; 95% CI: 4.2-13.7) and abnormal CSF total protein (OR: 2.1; 95% CI: 1.1-3.7). CONCLUSIONS: In this large study of aviremic patients receiving ART, CSF viral escape was uncommon and was linked to evidence of central nervous system inflammation and the use of protease inhibitors, but not with worse neurocognitive performance.
Authors: Dianne Langford; Jennifer Marquie-Beck; Sergio de Almeida; Deborah Lazzaretto; Scott Letendre; Igor Grant; J Allen McCutchan; Eliezer Masliah; Ronald J Ellis Journal: J Neurovirol Date: 2006-04 Impact factor: 2.643
Authors: A Antinori; G Arendt; J T Becker; B J Brew; D A Byrd; M Cherner; D B Clifford; P Cinque; L G Epstein; K Goodkin; M Gisslen; I Grant; R K Heaton; J Joseph; K Marder; C M Marra; J C McArthur; M Nunn; R W Price; L Pulliam; K R Robertson; N Sacktor; V Valcour; V E Wojna Journal: Neurology Date: 2007-10-03 Impact factor: 9.910
Authors: Alexia Cusini; Pietro L Vernazza; Sabine Yerly; Laurent A Decosterd; Bruno Ledergerber; Christoph A Fux; Janine Rohrbach; Nicolas Widmer; Bernhard Hirschel; Roman Gaudenz; Matthias Cavassini; Thomas Klimkait; Franziska Zenger; Chistine Gutmann; Milos Opravil; Huldyrich F Günthard Journal: J Acquir Immune Defic Syndr Date: 2013-01-01 Impact factor: 3.731
Authors: Elena Izmailova; Frederic M N Bertley; Qian Huang; Norbert Makori; Christopher J Miller; Richard A Young; Anna Aldovini Journal: Nat Med Date: 2003-01-21 Impact factor: 53.440
Authors: Scott Letendre; Jennifer Marquie-Beck; Edmund Capparelli; Brookie Best; David Clifford; Ann C Collier; Benjamin B Gelman; Justin C McArthur; J Allen McCutchan; Susan Morgello; David Simpson; Igor Grant; Ronald J Ellis Journal: Arch Neurol Date: 2008-01
Authors: Qing Ma; Andrew J Ocque; Gene D Morse; Chelsea Sanders; Alina Burgi; Susan J Little; Scott L Letendre Journal: Clin Infect Dis Date: 2020-08-14 Impact factor: 9.079
Authors: Sérgio Monteiro de Almeida; Indianara Rotta; Ana Paula de Pereira; Bin Tang; Anya Umlauf; Cléa Elisa Lopes Ribeiro; Scott Letendre; Ronald J Ellis Journal: J Neurovirol Date: 2020-01-30 Impact factor: 2.643
Authors: Jennifer O Lam; Catherine Lee; Paola Gilsanz; Craig E Hou; Wendy A Leyden; Derek D Satre; Jason A Flamm; William J Towner; Michael A Horberg; Michael J Silverberg Journal: AIDS Date: 2022-03-01 Impact factor: 4.177
Authors: Sheeba Arnold Anteraper; Kaundinya Gopinath; Michael J Hoch; Drenna Waldrop-Valverde; Donald Franklin; Scott L Letendre; Susan Whitfield-Gabrieli; Albert M Anderson Journal: J Neurovirol Date: 2021-03-05 Impact factor: 2.643
Authors: A Barco; S Orlando; G Stroffolini; V Pirriatore; A Lazzaro; D Vai; G Guastamacchia; G Noce; C Atzori; M Trunfio; S Bonora; G Di Perri; A Calcagno Journal: J Neurovirol Date: 2022-01-19 Impact factor: 2.643